GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Cyclically Adjusted PB Ratio

CEL-SCI (CEL-SCI) Cyclically Adjusted PB Ratio : 1.70 (As of Jun. 01, 2024)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Cyclically Adjusted PB Ratio?

As of today (2024-06-01), CEL-SCI's current share price is $1.21. CEL-SCI's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $0.71. CEL-SCI's Cyclically Adjusted PB Ratio for today is 1.70.

The historical rank and industry rank for CEL-SCI's Cyclically Adjusted PB Ratio or its related term are showing as below:

CVM' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.05   Med: 0.49   Max: 3.78
Current: 1.71

During the past years, CEL-SCI's highest Cyclically Adjusted PB Ratio was 3.78. The lowest was 0.05. And the median was 0.49.

CVM's Cyclically Adjusted PB Ratio is ranked better than
50.46% of 654 companies
in the Biotechnology industry
Industry Median: 1.745 vs CVM: 1.71

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CEL-SCI's adjusted book value per share data for the three months ended in Mar. 2024 was $0.264. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.71 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


CEL-SCI Cyclically Adjusted PB Ratio Historical Data

The historical data trend for CEL-SCI's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Cyclically Adjusted PB Ratio Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 3.01 4.21 1.59 1.22

CEL-SCI Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 2.03 1.22 3.42 2.69

Competitive Comparison of CEL-SCI's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, CEL-SCI's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Cyclically Adjusted PB Ratio falls into.



CEL-SCI Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CEL-SCI's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.21/0.71
=1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CEL-SCI's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.264/131.7762*131.7762
=0.264

Current CPI (Mar. 2024) = 131.7762.

CEL-SCI Quarterly Data

Book Value per Share CPI Adj_Book
201406 5.692 100.560 7.459
201409 3.188 100.428 4.183
201412 3.235 99.070 4.303
201503 0.094 99.621 0.124
201506 0.876 100.684 1.147
201509 -1.060 100.392 -1.391
201512 0.679 99.792 0.897
201603 -0.545 100.470 -0.715
201606 -0.650 101.688 -0.842
201609 -0.109 101.861 -0.141
201612 0.581 101.863 0.752
201703 -0.355 102.862 -0.455
201706 0.010 103.349 0.013
201709 -0.280 104.136 -0.354
201712 -0.365 104.011 -0.462
201803 -0.184 105.290 -0.230
201806 -0.064 106.317 -0.079
201809 0.000 106.507 0.000
201812 0.097 105.998 0.121
201903 0.032 107.251 0.039
201906 0.034 108.070 0.041
201909 0.146 108.329 0.178
201912 0.194 108.420 0.236
202003 0.327 108.902 0.396
202006 0.494 108.767 0.599
202009 0.509 109.815 0.611
202012 0.725 109.897 0.869
202103 0.718 111.754 0.847
202106 1.392 114.631 1.600
202109 1.308 115.734 1.489
202112 1.187 117.630 1.330
202203 1.042 121.301 1.132
202206 0.893 125.017 0.941
202209 0.740 125.227 0.779
202212 0.608 125.222 0.640
202303 0.460 127.348 0.476
202306 0.330 128.729 0.338
202309 0.279 129.860 0.283
202312 0.253 129.419 0.258
202403 0.264 131.776 0.264

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CEL-SCI  (AMEX:CVM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CEL-SCI Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI (CEL-SCI) Business Description

Industry
Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182